AI-generated summary
The authors report a pilot study of red laser therapy (635 nm) in 53 patients with confirmed cutaneous leishmaniasis, treating 123 lesions over four weekly sessions. At 10 months, 91% of patients with early, low-grade lesions showed complete response and 9% partial response, while patients with high-grade lesions showed no response. The authors describe the treatment as promising for early-stage lesions.
- Participants
- 53
- Who or what was studied
- Patients with confirmed cutaneous leishmaniasis, divided into low-grade (Grade I and II) and high-grade (Grade III-V) lesion groups
- Wavelengths
- 635 nm
- Limits stated in the abstract
- The abstract describes a pilot study, and it does not report a control group or the sample size per group.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on doi.org.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 635 nm
- Energy density (fluence)
- 75 J/cm2
- Power
- 300 mW
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Low-level laser therapy, GRADE, Laser, Pilot study, Wavelength, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.